Abstract
The role of high-dose therapy in the management of multiple myeloma in patients older than 65 years has, to date, been uncertain. The current article establishes both survival benefit and improved response duration in patients up to the age of 70 years with multiple myeloma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3000-3001 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 104 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 15 2004 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology